Search

Your search keyword '"N'Fally, Magassouba"' showing total 5 results
Start Over Author "N'Fally, Magassouba"
5 results on '"N'Fally, Magassouba"'

1. Temporal evolution of the humoral antibody response after Ebola virus disease in Guinea: a 60-month observational prospective cohort study

Author

Mamadou Saliou Kalifa Diallo, MSc, Ahidjo Ayouba, PhD, Alpha Kabinet Keita, PhD, Guillaume Thaurignac, MSc, Mamadou Saliou Sow, MD, Cécé Kpamou, MSc, Thierno Alimou Barry, MD, Philippe Msellati, PhD, Jean-François Etard, PhD, Martine Peeters, PhD, René Ecochard, ProfPhD, Eric Delaporte, ProfPhD, Abdoulaye Toure, PhD, Ahidjo Ayouba, Sylvain Baize, Kaba Bangoura, Alimou Barry, Moumié Barry, Mamoudou Cissé, Mohammed Cissé, Eric Delaporte, Jean-François Delfraissy, Christelle Delmas, Alice Desclaux, Saliou Bella Diallo, Mamadou Safiatou Diallo, Mariama Sadjo Diallo, Jean-François Étard, Cécile Etienne, Ousmane Faye, Ibrahima Fofana, Bruno Granouillac, Suzanne Izard, Djenaba Kassé, Alpha Kabinet Keita, Sakoba Keita, Lamine Koivogui, Cécé Kpamou, Christine Lacarabaratz, Sandrine Leroy, Claire Levy Marchal, Yves Levy, N'Fally Magassouba, Laura March, Vincent Mendiboure, Philippe Msellati, Harissatou Niane, Martine Peeters, Yves-Marie Pers, Hervé Raoul, Sidi Lamine Sacko, Ibrahima Savané, Mamadou Saliou Sow, Bernard Taverne, Abdoulaye Touré, Fodé Amara Traoré, Falaye Traoré, Yamoussa Youla, and Yazdan Yazdanpanah

Subjects
Medicine (General), R5-920, Microbiology, QR1-502
Abstract

Summary: Background: Insufficient long-term data are available on antibody kinetics in survivors of Ebola virus disease (EVD). Likewise, few studies, with very small sample sizes, have investigated cross-reactions between Ebolavirus spp. In this study, we aimed to assess the humoral antibody response and its determinants in survivors of EVD and assess cross-reactivity of antibodies between diverse Ebolavirus spp. Methods: In this observational, prospective cohort study, we collected blood samples from patients from three recruitment sites in Guinea included in the Postebogui study, and we assessed IgG antibody binding to recombinant glycoprotein, nucleoprotein, and 40-kDa viral protein (VP40) of Zaire (EBOV), Bundibugyo (BDBV), and Sudan (SUDV) Ebolaviruses. Participants from the PostEbogui study, from whom we had at least one blood sample that could be tested for the presence of antibodies, were eligible for this analysis. Patients in the PostEbogui study were assessed clinically at inclusion, 1 month and 3 months later, and subsequently every 6 months for up to 60 months after discharge from the Ebola treatment centre. We explored predictors of glycoprotein, nucleoprotein, and VP40 antibody concentrations through a linear mixed model. A logistic mixed model was done to estimate the probability of seropositivity and associated determinants. We assessed cross-reactivity by use of hierarchical cluster analysis. Findings: Of the 802 patients included in the Postebogui study, 687 were included in our analyses. 310 (45%) patients were men and 377 (55%) were women, with an overall median age at the time of the first blood sample of 27·3 years (IQR 19·5–38·2). We observed an overall significant decrease over time of EBOV antibodies, with antibodies against nucleoproteins decreasing more rapidly. At 60 months after discharge from the Ebola treatment centre, the probability of having antibodies against glycoproteins was 76·2% (95% CI 67·2–83·3), against nucleoproteins was 59·4% (46·3–71·3), and against VP40 was 60·9% (51·4–69·8). Persistence of EBOV RNA in semen was associated with higher concentrations of IgG antibodies against nucleoprotein EBOV antigens. Individually, we observed in some survivors an antibody wax-and-wane pattern. The proportion of cross-reactions was highest between glycoproteins from Kissidougou and Mayinga EBOV strains (94·5%, 95% CI 92·5–96·1), followed by EBOV VP40 and BDBV VP40 (88·3%, 85·7–90·6), and EBOV VP40 and SUDV VP40 (83·3%, 80·3–86·1). Interpretation: The probability for survivors of EVD to have antibodies against one or more EBOV antigens remained high, although approximately 25% of survivors had undetectable antibodies, which could have implications, such as a possible decreasing population immunity, for future Ebola outbreaks in the same region. Funding: Reacting–Institut National de la Santé et de la Recherche Médicale, Institut de Recherche pour le Developpement, and Montpellier Université d'Excellence.

Published
2021
Full Text
View/download PDF

2. Clinical evaluation of the BioFire FilmArray ® BioThreat-E test for the diagnosis of Ebola Virus Disease in Guinea

Author

Corentin Gauby, Ousmane Faye, Françoise Gay-Andrieu, Ahmadou Doré, N'Fally Magassouba, Matt Scullion, Véronique Ligeon-Ligeonnet, Brigitte Dacosta, Valentina Picot, Christophe N. Peyrefitte, Jean Louis Machuron, Fodé Kourouma, Christophe Longuet, Mark Miller, and Cynthia L. Phillips

Subjects
0301 basic medicine, Saliva, Ebola Zaire virus, medicine.medical_specialty, Ebola virus, business.industry, 030106 microbiology, Outbreak, Context (language use), Urine, Disease, medicine.disease_cause, Virology, 03 medical and health sciences, Infectious Diseases, Internal medicine, medicine, business, Clinical evaluation
Abstract

Background The recent West Africa Ebola outbreak highlighted the need to provide access to rapid, safe and reliable Ebola Virus Disease diagnostics. Objectives The objective of this field study was to assess the clinical performance of the FilmArray® BioThreat-E test for the detection of Ebola Zaire virus in whole blood in symptomatic patients suspected of Ebola Virus Disease in Conakry (Guinea) from March to July 2015. Study design The BioThreat-E test was compared to the two RT-PCRs, using serum, implemented at Donka Hospital in the emergency context: an in-house developed quantitative one-step RT-PCR adapted from the Weidmann technique, and the RealStar® Filovirus RT-PCR Kit 1.0 (Altona-Diagnostics). We also assessed the performance of this assay in noninvasive specimens (urine and saliva) to detect infected patients. Results Of 135 patients enrolled and eligible for performance assessment on whole blood, the sensitivity was 95.7% [95% CI: 85.5–99.5] and specificity 100% [95% CI: 95.9–100]. Of the 37 symptomatic infected patients able to provide saliva and/or urine samples, 34 of the 35 saliva samples and all 3 of the urine samples were positive with the BioThreat-E test. Conclusions This study showed that the FilmArray BioThreat-E test performs comparably to conventional molecular tests under field conditions, providing results and interpretation in approximately 1 h. Due to its operational characteristics, it can be easily deployed in the field during an epidemic and could also be a useful tool for post-outbreak surveillance.

Published
2017

3. Ocular Complications in Survivors of the Ebola Outbreak in Guinea

Author

Esther Hereth-Hebert, Mamadou Oury Bah, Jean François Etard, Mamadou Saliou Sow, Serge Resnikoff, Christine Fardeau, Abdoulaye Toure, Alexis Niouma Ouendeno, Isaac Ceougna Sagno, Laura March, Suzanne Izard, Pierre Louis Lama, Moumié Barry, Eric Delaporte, Ahidjo Ayouba, Sylvain Baize, Amadou Camara, Mohammed Cissé, Jean-François Delfraissy, Christelle Delmas, Alice Desclaux, Saliou Bella Diallo, Mariama Sadio Diallo, Jean François Étard, Cécile Etienne, Bruno Granouillac, Djenaba Kassé, Alpha Kabinet Keita, Sakoba Keita, Esther Hereth Hébert, Lamine Koivugui, Cece Kpamou, Christine Lacarabaratz, Sandrine Leroy, Claire Levy Marchal, Yves Levy, N'Fally Magassouba, Martine Peeters, Hervé Raoul, Ibrahima Savané, Bernard Taverne, Abdoulaye Touré, Yazdan Yazdanpanah, Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Université Montpellier 1 (UM1), Service d'Ophtalmologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

Subjects
Adult, Male, Pediatrics, medicine.medical_specialty, Adolescent, Eye Infections, Viral, Diagnostic Techniques, Ophthalmological, medicine.disease_cause, Disease Outbreaks, Uveitis, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Case fatality rate, medicine, Humans, Prospective Studies, Survivors, 030212 general & internal medicine, [SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory Organs, Child, Prospective cohort study, Keratitis, Ebola virus, business.industry, Incidence, Outbreak, Episcleritis, Hemorrhagic Fever, Ebola, Middle Aged, Eye infection, Ebolavirus, medicine.disease, 3. Good health, Surgery, Ophthalmology, Child, Preschool, DNA, Viral, 030221 ophthalmology & optometry, Female, Guinea, business, Follow-Up Studies, Scleritis, Cohort study
Abstract

International audience; PURPOSE:The Ebola outbreak of 2013-2016 severely affected West Africa and resulted in 2544 deaths and 1270 survivors in Guinea, the country where it began. This Ebola virus was the Zaire strain of the virus family Filoviridae. In this outbreak the case fatality rate was about 67%. The survivors, declared cured after 2 negative blood polymerase chain reaction (PCR) results, face psychosocial disorders and rheumatic, ear-nose-throat, neurocognitive, and ophthalmologic complications. The goal of this study was to detect and describe ocular complications afflicting these survivors and to observe their occurrence and recurrences.DESIGN:Prospective observational cohort study.METHODS:This prospective observational multicenter cohort study was initiated in March 2015. The cohort study included 341 survivors followed up in the infectious disease ward of Conakry, Forecariah, and Nzérékoré as of May 2016. The patients received multidisciplinary medical follow-up expected to last at least 1 year that included an eye examination as part of complete, free treatment.RESULTS:Systematic examination of 341 patients revealed 46 cases of uveitis (13.5%), 6 cases of episcleritis (1.8%), and 3 cases of interstitial keratitis (0.9%). Uveitis was most frequently unilateral (78.3%) and anterior (47.8%) and occurred within the 2 months after discharge from the Ebola treatment center. Moreover, uveitis relapses were found up to 13 months after the negative PCR result for Ebola in the blood.CONCLUSION:Nearly 1 out of 6 survivors presented ocular disorders after discharge from the Ebola treatment center. An ophthalmologic follow-up for Ebola-infected patients should start, if possible, during the acute phase of the disease and last more than 1 year. Treatment guidelines need to be urgently developed and implemented.

Published
2017

4. Clinical evaluation of the BioFire FilmArray

Author

Françoise, Gay-Andrieu, N'Fally, Magassouba, Valentina, Picot, Cynthia L, Phillips, Christophe N, Peyrefitte, Brigitte, Dacosta, Ahmadou, Doré, Fode, Kourouma, Véronique, Ligeon-Ligeonnet, Corentin, Gauby, Christophe, Longuet, Matt, Scullion, Ousmane, Faye, Jean Louis, Machuron, and Mark, Miller

Subjects
Adult, Male, Time Factors, Hemorrhagic Fever, Ebola, Ebolavirus, Real-Time Polymerase Chain Reaction, Sensitivity and Specificity, Disease Outbreaks, Molecular Diagnostic Techniques, Humans, RNA, Viral, Female, Guinea, Saliva
Abstract

The recent West Africa Ebola outbreak highlighted the need to provide access to rapid, safe and reliable Ebola Virus Disease diagnostics.The objective of this field study was to assess the clinical performance of the FilmArrayThe BioThreat-E test was compared to the two RT-PCRs, using serum, implemented at Donka Hospital in the emergency context: an in-house developed quantitative one-step RT-PCR adapted from the Weidmann technique, and the RealStarOf 135 patients enrolled and eligible for performance assessment on whole blood, the sensitivity was 95.7% [95% CI: 85.5-99.5] and specificity 100% [95% CI: 95.9-100]. Of the 37 symptomatic infected patients able to provide saliva and/or urine samples, 34 of the 35 saliva samples and all 3 of the urine samples were positive with the BioThreat-E test.This study showed that the FilmArray BioThreat-E test performs comparably to conventional molecular tests under field conditions, providing results and interpretation in approximately 1h. Due to its operational characteristics, it can be easily deployed in the field during an epidemic and could also be a useful tool for post-outbreak surveillance.

Published
2016

5. New Evidence of Long-lasting Persistence of Ebola Virus Genetic Material in Semen of Survivors

Author

Mamadou S, Sow, Jean-François, Etard, Sylvain, Baize, N'Fally, Magassouba, Ousmane, Faye, Philippe, Msellati, Abdoulaye, Touré, Ibrahima, Savane, Moumié, Barry, Eric, Delaporte, and Y, Lévy

Subjects
Adult, Male, Time Factors, Hemorrhagic Fever, Ebola, Middle Aged, Ebolavirus, Young Adult, Pregnancy, Semen, Humans, RNA, Viral, Female, Guinea, Follow-Up Studies
Abstract

Ninety-eight semen specimens were obtained for Ebola virus (EBOV) RNA screening from 68 men in Guinea during the convalescent phase of EBOV infection. Ten samples from 8 men were positive for EBOV up to 9 months after onset of the disease, with decreasing trends in the proportion of positive samples and the level of viral RNA. Safe sex practices should be observed after discharge from treatment centers.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results